Anthony Elias

24.0k total citations · 3 hit papers
205 papers, 9.8k citations indexed

About

Anthony Elias is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Anthony Elias has authored 205 papers receiving a total of 9.8k indexed citations (citations by other indexed papers that have themselves been cited), including 144 papers in Oncology, 97 papers in Pulmonary and Respiratory Medicine and 38 papers in Molecular Biology. Recurrent topics in Anthony Elias's work include Sarcoma Diagnosis and Treatment (37 papers), Lung Cancer Treatments and Mutations (30 papers) and Cancer Treatment and Pharmacology (27 papers). Anthony Elias is often cited by papers focused on Sarcoma Diagnosis and Treatment (37 papers), Lung Cancer Treatments and Mutations (30 papers) and Cancer Treatment and Pharmacology (27 papers). Anthony Elias collaborates with scholars based in United States, United Kingdom and Switzerland. Anthony Elias's co-authors include Lowell E. Schnipper, Karen H. Antman, Catherine Wheeler, Emil Frei, Joseph P. Eder, Lois Ayash, Louise Ryan, Jennifer K. Richer, George D. Demetri and William J. Gradishar and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Investigation.

In The Last Decade

Anthony Elias

199 papers receiving 9.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Effect of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor on Chemotherapy-Induced Myelosuppression

1988 538 citations Anthony Elias, Emil Frei et al. profile →
Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial

2016 436 citations William D. Tap, Anthony Elias et al. profile →
Male breast cancer: a disease distinct from female breast cancer

2018 230 citations Ayca Gucalp, Tiffany A. Traina et al. Breast Cancer Research and Treatment profile →

Peers

Countries citing papers authored by Anthony Elias

Since Specialization

Citations

This map shows the geographic impact of Anthony Elias's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anthony Elias with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anthony Elias more than expected).

Fields of papers citing papers by Anthony Elias

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anthony Elias. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anthony Elias. The network helps show where Anthony Elias may publish in the future.

Co-authorship network of co-authors of Anthony Elias

This figure shows the co-authorship network connecting the top 25 collaborators of Anthony Elias. A scholar is included among the top collaborators of Anthony Elias based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anthony Elias. Anthony Elias is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Long-term Safety and Clinical Activity in Patients with Conventional Chondrosarcoma 2025 ·Clinical Cancer Research ·William D. Tap, Gregory M. Coté, Howard A. Burris, Lia Gore, Anthony Elias, M. Beeram, Anthony P. Conley, Diego A. Gianolio, (unknown), (unknown), Jonathan C. Trent	1
2	Safety and Efficacy of Toripalimab in Patients with Cholangiocarcinoma: An Open-Label, Phase 1 Study 2025 ·PubMed ·Aung Naing, Amit Mahipal, Milind Javle, Judy Wang, Todd M. Bauer, David L. Bajor, Anthony Elias, Anthony F. Shields, Elizabeth J. Davis, Sant P. Chawla, (unknown), John D. Powderly, Gina Z. D’Amato, Christian F. Meyer, Xiongwen Tang, Sheng Yao, Patricia Keegan	0
3	A Single-Arm Phase 2 Trial of Doxorubicin Plus Zalifrelimab (Anti–CTLA-4 Antibody) and Balstilimab (Anti–PD-1 Antibody) in Advanced/Metastatic Soft Tissue Sarcomas 2025 ·Clinical Cancer Research ·Breelyn A. Wilky, (unknown), Alessandra Maleddu, (unknown), (unknown), Dexiang Gao, (unknown), (unknown), (unknown), Sofia Chaudhry, (unknown), (unknown), Eduardo Dávila, Anthony Elias	1
4	Proteasome Inhibition Sensitizes Liposarcoma to MDM2 Inhibition with Nutlin-3 by Activating the ATF4/CHOP Stress Response Pathway 2023 ·Cancer Research ·Michael P. Ludwig, Matthew D. Galbraith, (unknown), Amanda A. Hill, Michael R. Clay, (unknown), Breelyn A. Wilky, Anthony Elias, Joaquı́n M. Espinosa, Kelly D. Sullivan	8
5	Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II Study 2022 ·Clinical Cancer Research ·Vivek Subbiah, Irene Braña, Alessandra Longhi, Valentina Boni, Jean‐Pierre Delord, Ahmad Awada, Pascaline Boudou‐Rouquette, John Sarantopoulos, Geoffrey I. Shapiro, Anthony Elias, Ravin Ratan, Cristian Fernández, Carmen Kahatt, Martín Cullell-Young, Mariano Siguero, Ali Zeaiter, Sant P. Chawla	18
6	Mutual exclusivity of ESR1 and TP53 mutations in endocrine resistant metastatic breast cancer 2022 ·npj Breast Cancer ·Zheqi Li, Nicole S. Spoelstra, Matthew J. Sikora, Sharon B. Sams, Anthony Elias, Jennifer K. Richer, Adrian V. Lee, Steffi Oesterreich	17
7	Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring CCNE1 Amplification 2022 ·Journal of Clinical Oncology ·Siqing Fu, Shuyang Yao, Yuan Yuan, Rebecca A. Previs, Anthony Elias, Richard D. Carvajal, Thomas J. George, Ying Yuan, (unknown), Shannon N. Westin, (unknown), Ecaterina E. Dumbrava, Daniel D. Karp, Sarina A. Piha‐Paul, Apostolia M. Tsimberidou, Jordi Rodón, Naoko Takebe, Karen H. Lu, Khandan Keyomarsi, Funda Meric‐Bernstam	50
8	Identifying the Gate-Opening Mechanism in the Flexible Metal–Organic Framework UTSA-300 2022 ·Inorganic Chemistry ·Shree Ram Acharya, Anthony Elias, Kui Tan, Stephanie Jensen, Rui‐Biao Lin, Banglin Chen, Michael D. Gross, Timo Thonhauser	10
9	Activity of Combined Androgen Receptor Antagonism and Cell Cycle Inhibition in Androgen Receptor Positive Triple Negative Breast Cancer 2021 ·Molecular Cancer Therapeutics ·Jessica L. Christenson, (unknown), Michelle M. Williams, Nicole S. Spoelstra, Kenneth L. Jones, G. Devon Trahan, (unknown), (unknown), Anthony Elias, Joel R. Eisner, Jennifer K. Richer	28
10	Neoadjuvant endocrine therapy expands stromal populations that predict poor prognosis in estrogen receptor‐positive breast cancer 2021 ·Molecular Carcinogenesis ·Heather M. Brechbuhl, Mengyu Xie, (unknown), (unknown), Kiran Paul, (unknown), Susan M. Edgerton, Philip Owens, Sharon B. Sams, Anthony Elias, Carol A. Sartorius, Aik Choon Tan, Peter Kabos	5
11	Clinical outcomes of breast cancer patients treated in phase I clinical trials at University of Colorado Cancer Center 2020 ·Cancer Medicine ·Jennifer Weiss, (unknown), (unknown), Dexiang Gao, Christine M. Fisher, Anthony Elias, Virginia F. Borges, Peter Kabos, S. Lindsey Davis, Stephen Leong, S. Gail Eckhardt, Jennifer R. Diamond	1
12	Endocrine therapy and related issues in hormone receptor-positive early breast cancer: a roundtable discussion by the breast cancer therapy expert group (BCTEG) 2018 ·Breast Cancer Research and Treatment ·Jame Abraham, Humberto Caldera, Robert E. Coleman, Anthony Elias, Matthew P. Goetz, Muaiad Kittaneh, Elyse E. Lower, Reshma Mahtani, E. Mamounas, Mark D. Pegram, Hope S. Rugo, Lee S. Schwartzberg, Tiffany A. Traina, (unknown)	9
13	A Phase I/Ib Study of Enzalutamide Alone and in Combination with Endocrine Therapies in Women with Advanced Breast Cancer 2017 ·Clinical Cancer Research ·Lee S. Schwartzberg, Denise A. Yardley, Anthony Elias, Manish R. Patel, Patricia LoRusso, Howard A. Burris, Ayca Gucalp, Amy Peterson, Martha Blaney, Joyce Steinberg, Jacqueline A. Gibbons, Tiffany A. Traina	42
14	Androgen Receptor Supports an Anchorage-Independent, Cancer Stem Cell-like Population in Triple-Negative Breast Cancer 2017 ·Cancer Research ·Valerie N. Barton, Jessica L. Christenson, Melita A. Gordon, Lisa I. Greene, Thomas J. Rogers, (unknown), Beatrice Babbs, Nicole S. Spoelstra, Nicholas C. D’Amato, Anthony Elias, Jennifer K. Richer	54
15	Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): Results from I-SPY 2. 2017 ·Journal of Clinical Oncology ·Rita Nanda, Minetta C. Liu, Christina Yau, Smita Asare, Nola Hylton, Laura van’t Veer, Jane Perlmutter, Anne M. Wallace, A. Jo Chien, Andres Forero‐Torres, Erin D. Ellis, Heather Han, Amy S. Clark, Kathy S. Albain, Judy C. Boughey, Anthony Elias, Donald A. Berry, Douglas Yee, Angela DeMichele, Laura Esserman	158
16	Fibroblast Subtypes Regulate Responsiveness of Luminal Breast Cancer to Estrogen 2016 ·Clinical Cancer Research ·Heather M. Brechbuhl, Jessica Finlay-Schultz, Tomomi M. Yamamoto, Austin E. Gillen, Diana M. Cittelly, Aik Choon Tan, Sharon B. Sams, Manoj M. Pillai, Anthony Elias, William A. Robinson, Carol A. Sartorius, Peter Kabos	164
17	Multiple Molecular Subtypes of Triple-Negative Breast Cancer Critically Rely on Androgen Receptor and Respond to Enzalutamide In Vivo 2015 ·Molecular Cancer Therapeutics ·Valerie N. Barton, Nicholas C. D’Amato, Melita A. Gordon, Hanne Lind, Nicole S. Spoelstra, Beatrice Babbs, Richard E. Heinz, Anthony Elias, Paul Jedlicka, Britta M. Jacobsen, Jennifer K. Richer	174
18	Neutropenic enterocolitis as a complication of high dose chemotherapy with stem cell rescue in patients with solid tumors 1998 ·Cancer ·David Avigan, Paul G. Richardson, Anthony Elias, George D. Demetri, Michael Shapiro, Lowell E. Schnipper, Catherine Wheeler	28
19	High-Dose Chemotherapy with Autologous Stem Cell Support for Breast Cancer: A Review of the Dana-Farber Cancer Institute/Beth Israel Hospital Experience 1993 ·Journal of Hematotherapy ·Lois Ayash, Anthony Elias, Catherine Wheeler, Isidore Tepler, Gary N. Schwartz, Lowell E. Schnipper, Emil Frei, Karen H. Antman	3
20	The Use of G-CSF or GM-CSF Mobilized Peripheral Blood Progenitor Cells (PBPC) Alone or to Augment Marrow as Hematologic Support of Single or Multiple Cycle High-Dose Chemotherapy 1993 ·Journal of Hematotherapy ·Anthony Elias, Lois Ayash, I Tepler, C Wheeler, Gary N. Schwartz, Rosemary Mazanet, Lowell E. Schnipper, E Frei, Karen H. Antman	8

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact